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SUMMARY
BACKGROUND
The interactions between pressure and volume overload that occur in hypertension lead to 
different patterns of cardiac hypertrophy and to increase in natriuretic peptides (NPs). The 
profiles of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) synthesis 
and secretion have been investigated in models of hypertension. However, the different 
evolution of these profiles during the acute and chronic periods of pressure overload-induced 
cardiac hypertrophy is still unknown. For this reason, we studied one-kidney, one clip model 
using Sprague-Dawley rats at weeks 2, 4, 6 and 12 and correlated the evolution of these 
profiles with cardiac hypertrophy and hypertension.
We observed a positive correlation between blood pressure elevation and the degree of 
cardiac hypertrophy, with a time-dependent increase in both parameters from week 2. Levels 
of BNP expression showed an early increase after 2 weeks of treatment while ANP increased 
significantly after 6 weeks. Yet, the increase in ANP expression was gradual, allowing its 
correlation with hypertrophy and hypertension.
The NP expression has a differential response in the early stages of the development of 
hypertrophy induced by the renovascular model, with an early increase in BNP expression. 
Once hypertrophy develops, BNP expression is no longer specific and the increase of both 
NPs depends on and correlates with the degree of cardiac hypertrophy.
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1K1C  1 kidney, 1 clip
ANP Atrial natriuretic peptide
mRNA Messenger ribonucleic acid
BNP B-type natriuretic peptide
CNP C-Type natriuretic peptide
RAW Right atrial weight
LAW Left atrial weight
BW Body weight
HW  Heart weight
LWW Lung wet weight
NP Natriuretic peptide
SBP Systolic blood pressure
LDW Lung dry weight
RVW Right ventricular weight
LVW Left ventricular weight
RV Renovascular
Hypertension may produce different patterns 
of ventricular remodelling as a result of the 
pathophysiological processes triggered by the 
interaction between pressure and volume overloads. 
(1-3) In the early stages of cardiac hypertrophy, 
cardiomyocytes growth of is an adaptive response 
to increased functional demands of the heart. (4) 
Transition to pathological hypertrophy involves 
structural and functional changes, resulting in the 
predominance of the fetal gene programming with 
reactivation of the cardiac fetal phenotype. Thus, the 
endocrine and paracrine function of the heart increases 
the production of natriuretic peptides (NPs). (5, 6)
The family of NPs is constituted by three peptide 
hormones, atrial natriuretic peptide (ANP), type-B 
natriuretic peptide (BNP) and type-C natriuretic 
peptide (CNP). (7-9) These peptides reduce blood 
pressure as they produce diuresis, natriuresis and 
vasodilation. The also have anti-inflammatory effects 
and inhibit fibrosis and the hypertrophic growth of the 
myocardium. (10-12)
Renovascular (RV) hypertension increases left 
ventricular afterload with concomitant neurohumoral 
activation, producing cardiac hypertrophy and 
remodelling. In 1 kidney, 1 clip (1K-1C) Goldblatt model 
of renovascular hypertension, activation of the renin-
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RESULTS
Time course of hypertension and cardiac hypertrophy
SP was greater in the experimental groups vs. the sham 
groups since 2 weeks after surgery (160 mm Hg), and 
this increase was time-dependent in the RV groups, 
reaching 200 mmHg after 12 weeks (Figure A).
Cardiac hypertrophy, indicated by the HW/BW ratio, 
had a similar behavior (Figure 1B).
Table 1 shows the coefficients of heart and cardiac 
chambers hypertrophy. Left ventricular hypertrophy 
(LVW/BW) was noted from week 2, remained stable 
between weeks 4 to 6, and presented a significant 
increase in week 12. Increase in RVW/BW ratio was 
later, showing a significant raise in weeks 6 and 12, 
with similar values in both periods. Atrial remodelling 
was evident at week 4; increase in the LAW/BW ratio 
was time-dependent, while RAW/BW ratio increased 
only at week 12. 
There were no significant differences in the W/D ratio 
(data not included) in the sham groups or experimental 
groups; thus, pulmonary edema and heart failure were 
ruled out in all groups.
Cardiac chamber gene expression of ANP and BNP
The time course (2, 4, 6 and 12 weeks after surgery) 
MATERIAL AND METHODS
angiotensin-aldosterone system is rapidly followed 
by sodium and water retention and complemented 
by activation of the sympathetic nervous system. 
(13) Although this activation is primarily focused on 
preserving contractile function, chronic sympathetic 
hyperactivity increases vascular resistance and 
promotes arrhythmias and ventricular remodelling. 
(14)
The synthesis and secretion of NPs have been 
widely studied in several models of hypertension, 
such as DOCA-Salt model, aortic banding, 2 kidneys, 
1clip model and 1K1C model. (15-23) In addition, NPs 
have been proposed as biomarkers of hemodynamic 
overload, severity and development in different 
cardiomyopathies. (23-26) However, the expression of 
NPs during the chronic evolution of the hypertensive 
process in the 1K1C pressure overload model has not 
been studied yet.
Animals and surgical procedures
Male Sprague Dawley rats weighing 180 -200 g were 
used. Animals were housed in a temperature controlled 
environment (21 ± 2 °C), illuminated with a 12:12 hours 
light-dark cycle (light from 7:00 am to 07:00 pm). They 
were fed standard diet and water at will. Animal care 
was in accordance with the international regulations 
recommended by the Asociación Argentina de Ciencia y 
Tecnología de Animales de Laboratorio (AACyTAL).
We studied animals with RV hypertension at 2 (RV2), 
4 (RV4), 6 (RV6) and 12 (RV12) weeks after partial 
occlusion of the right renal artery with a 0.28-mm clip 
and contralateral nephrectomy. All animals had their 
respective control (sham) groups, Sh2, Sh4, Sh6 and Sh12, 
which underwent sham surgery with opening, closure in 
planes and manipulation of the renal artery without clip 
placement.
Determination of systolic pressure
Tail-cuff systolic blood pressure (BS) was determined in 
conscious rats after 2, 4, 6 and 12 weeks of treatment and 
recorded on a polygraph Grass 7B between 9:00 am and 
01:00 pm, after 3 days of exercise training.
Plasma and tissue sample processing
After 2, 4, 6, and 12 weeks, the inferior vena cava was 
punctured and blood samples were collected in plastic 
tubes containing 15% w/v EDTA to obtain plasma. A 
solution of KCl 1M was injected through the same via 
to induce diastolic arrest. The hearts were excised and 
washed with phosphate-buffered (pH = 7.4) saline 
solution, rinsed and weighed. The cardiac chambers 
were dissected, weighed and stored at -70°C until being 
analyzed. The interventricular septum and interatrial 
septum were included within the left ventricle and left 
atrium, respectively.
The lungs were excised and washed with phosphate-buffered 
saline solution, rinsed and weighed. Representative 
fragments of lung tissue were obtained, weighed (wet lung 
weight, W) and stored at -70°C. Then, the fragments were 
rinsed at 86 °C until constant weight was reached (dry lung 
weight, D). The wet-to-dry lung weight (W/D) ratio was 
indicative of pulmonary edema. (27)
Body (BW), heart (HW), left ventricle (LVW), right ventricle 
(RVW), left atrial (LAW) and right atrial (RAW) weights 
were determined to estimate cardiac hypertrophy. Thus, 
we determined the HW/BW, LVW/BW, RVW/BW, LAW/BW 
and RAW/BW ratios as indicative of cardiac hypertrophy 
and cardiac chambers hypertrophy, respectively.
RNA extraction and Northern blot analysis
RNA was isolated from atrium and ventricular samples 
by Trizol (Invitrogen, Carlsbad, California, USA) reagent 
and analyzed using the Northern blot protocol. (16) The 
following probes were used: 1) a 600 bp HindIII/BamHI 
fragment containing rat ANP cDNA, 2) a 600 bp HindIII/
XbaI fragment containing mice BNP cDNA, and 3) a 1.2 
bk EcoRI fragment containing human GAPDH cDNA. The 
signal intensities of ANP and BNP were normalized to 
that of mRNA GAPDH.
Extraction and radioimmunoassay BNP in plasma samples
Plasma BNP was extracted using the method described 
by Sarda et al. (28, 29) A BNP-45 (Rat) kit (Phoenix 
Pharmaceuticals, Inc. Burlingame, CA, USA) was used for 
radioimmunoassay (RIA).
Statistical Analysis
Results are expressed as mean values ± standard error of 
the mean (SEM). The t test was used to compare the mean 
values between the sham groups and RV groups at different 
weeks after treatment. Single-factor ANOVA followed by 
Tukey-Kramer post-test was used to compare the different 
experimental groups (RV groups in different weeks), using 
software GraphPad Instat® (GraphPad Software Inc., San 
Diego, California, USA). Correlations were analyzed using 
Pearson’s linear correlation coefficient. A p value < 0.05 
was considered statistically significant.
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of ANP and BNP mRNA expression in the cardiac 
chambers was studied.
ANP mRNA presented a time-dependent increase in 
the left ventricle, reaching statistically significant 
values at week 6 (Figure 2 A). Changes in BNP 
were moderate and occurred earlier, with significant 
increase in group RV2 that remained stable until week 
6, rising again in week 12 (Figure 2 B). Increase in 
BNP mRNA expression at 6 and 12 weeks was lower 
compared to ANP mRNA expression (Figure 2 C).
In the right ventricle, ANP mRNA expression increased 
in the RV group only 12 weeks after treatment (Sh6: 
100.0 ± 1.0; RV6: 100.0 ± 1.5; Sh12: 108.2 ± 7.2; 
RV12: 482.2 ± 55.3*; the values are expressed in 
percentages of the corresponding value in the sham 
groups, mean ± SEM, n = 5-8; *p < 0.001). However, 
enhanced BNP mRNA expression occurred earlier, 
at 6 weeks (Sh6: 100.0 ± 5.7; RV6: 137.9 ± 40.9; 
Sh12: 100.0 ± 3.2; RV12: 200.7 ± 9.1*; the values are 
expressed in percentages of the corresponding value 
in the sham groups, mean ± SEM, n = 5-8; *p < 0.01). 
This behavior correlates with the increase in the 
RVW/BW ratio of groups RV6 and RV12, the only two 
groups which developed right ventricular hypertrophy. 
Despite ANP and BNP mRNA expression increased 
significantly in both ventricles, we did not find any 
changes in the atria (data not shown).
Profile of BNP secretion in plasma
Plasma BNP levels increased significantly in the RV 
model since week 4 (Figure 3 A), and this raise was 
also time-dependent.
Correlations between systolic pressure, hypertrophy and NP 
expression
A positive correlation was observed between cardiac 
Values expressed as percentage of the corresponding value in the sham groups, mean ± SEM LVW/BW: 
Left ventricular weight/body weight. RVW/BW: Right ventricular weight/body weight. LAW/BW: Left atrial 
weight/body weight. RAW/BW: Right atrial weight/body weight. * p < 0.05 versus Sh2. # p < 0.05 versus Sh4. 
& p < 0.05 versus Sh6. § p < 0.05 and §§ p < 0.001 versus Sh12.
Table 1. Hypertrophy of the 
different cardiac chambers
Fig 1. Changes in systolic 
pressure (SP) (pannel a) 
and cardiac hypertrophy, 
determined by heart weight/
body weight ratio (HW/
BW) (pannel b) according 
to treatment time. N = 149 
Pannel a: values are expressed 
as mean ±SEM, * p < 0.001 
versus the corresponding 
value in the sham groups; 
† p < 0.05 versus RV2; ‡ p < 
0.001 versus RV2; § p < 0-01 
versus RV6. Pannel b: values 
expressed as percentage of 
the corresponding value in 
the sham groups, mean ± 
SEM. * p < 0.05 versus Sh2. ** 
p < 0.01 versus Sh4 and Sh6. 
*** p < 0.001 versus Sh12. § p 
< 0.05 versus RV6.
Groups
Sh2
RV2
Sh4
RV4
Sh6
RV6
SH12
RV12
n
100
119 ± 3 *
100
127 ± 4 *
100
127 ± 5 &
100
146 ± 12 §
4-8
LVW/BW
100
100 ± 4 *
100
104 ± 9 *
100
131 ± 10 &
100
130 ± 7 §
4-8
RVW/BW
100
109 ± 9 *
100
125 ± 8 *
100
134 ± 10 &
100
153 ± 10 §
8-16
LAW/BW
100
98 ± 5 *
100
99 ± 6 *
100
102 ± 5 &
100
133 ± 6 §
8-16
RAW/BW
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DISCUSSION
Plasma renin activity is normal in 1K1C model; the 
initial increase in systolic pressure is due to early 
fluid and sodium retention with a transient elevation 
in plasma volume which was followed by a return to 
normal levels, while hypertension in chronic stages is 
associated with elevated peripheral resistance. (30, 31)
The present study evaluated the time-course of 
the synthesis and secretion of NPs ANP and BNP 
in relation with the degree of cardiac hypertrophy 
secondary to pressure overload in the model of 
renovascular hypertension 1K1C. RV treatment 
induced a time-dependent elevation of SP that reached 
200 mm Hg at 12 weeks. In addition, the degree of 
cardiac hypertrophy increased progressively and in 
parallel with the elevation of SP during the course of 
treatment. These results are consistent with the data 
found by Simone et al., (32) who studied rats after 8 
weeks of RV treatment and observed a relation between 
blood pressure and left ventricular mass index.
Cardiac hypertrophy has been associated with 
increased synthesis and secretion of ANP in the 
ventricles. (33) In coincidence, we found a positive 
correlation between ventricular ANP expression, 
cardiac hypertrophy index and left ventricular 
hypertrophy index, demonstrated by greater cardiac 
hypertrophy and left ventricular ANP mRNA 
expression with longer treatment time
BNP gene expression in both ventricles increases 
rapidly in response to hemodynamic overload, while 
increase in ANP expression appears in an advanced 
stage and has greater magnitude. Increased BNP 
expression in the left ventricle was noted from week 
2, remained stable until week 6 and presented a 
significant increase in week 12. Conversely, ANP 
presented a gradual increase from week 4, reached 
significant values at week 6 and continued rising 
in week 12. In consequence, BNP expression did 
not correlate with the degree of hypertrophy and 
hypertension as ANP. In the right ventricle, BNP 
expression also increased earlier compared to ANP. 
BNP mRNA expression increased since week 6, while 
ANP mRNA did not rise until week 12. This pattern 
correlates with right ventricular hypertrophy present 
hypertrophy index and SBP values (p = 0.0027, 
r = 0.9973 and r2 = 0.9946; Figure 4 A) and ANP 
expression in the left ventricle (p = 0.0048, r = 0.9522 
and r2 = 0.9067; Figure 4 B) during the studied 
periods. There was also a positive correlation between 
the latter and left ventricular hypertrophy index (p = 
0.0050, r = 0.8698 and r2 = 0.7566). As it can be noted, 
there was a gradual, time-dependent increase in blood 
pressure levels, NPs expression and development of 
cardiac hypertrophy.
Finally, BNP plasma levels showed a positive 
correlation with BNP mRNA expression in the left 
ventricle (p = 0.0004, r = 0.942922 and r2 = 0.8890; 
Figure 3 B).
Fig. 1. Natriuretic peptide expression in the left ventricle 
(LV). ANP mRNA expression in the LV (pannel a), BNP mRNA 
expression in the LV (pannel b) and percentage of increase 
in ANP and BNP mRNA expression in relation to treatment 
time (pannel c). All values expressed as percentage of the 
corresponding value in the sham groups, mean ± SEM, n = 5.8 
* p < 0.05, ** p < 0.01 y *** p < 0.001 versus sham. § p < 0.001 
versus RV6.
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in groups RV6 and RV12.
According to these results, we may suggest 
that left ventricular hypertrophy develops until 
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it counteracts the afterload, with HW/BW ratio 
values that remain quite similar between weeks 4 
and 6. During this period, left atrium enlargement 
begins, overloading of the pulmonary circulation. 
Thus, animals after 6 weeks of treatment show left 
and right ventricular hypertrophy, and left atrium 
enlargement. After 6 additional weeks (RV12), the 
left ventricle might not compensate for the increased 
afterload induced by renal artery stenosis, developing 
greater hypertrophy. We found neither pulmonary 
hypertension nor pulmonary congestion, as the W/D 
ratio, used to evaluate the presence of pulmonary 
edema, did not show any significant difference. The 
right ventricular hypertrophy remained during 6 
weeks as a consequence of increased overload, leading 
to right atrial enlargement in the group RV12. After 
12 weeks, we did not find clinical or morphometric 
signs of dilated cardiomyopathy as seen in the DOCA-
salt model of hypertension. (34) Therefore, changes 
in ANP and BNP synthesis and secretion can only be 
related with the development of cardiac hypertrophy. 
Left ventricular systolic pressure, developed pressure 
of the left ventricle and +dP/dt were elevated in the 
experimental model and to a similar extent in the 
groups RV6 and RV12, with absence of significant 
differences between weeks 6 and 12. (35) These left 
ventricular functional variables were incidental to 
hypertrophy with absence of heart failure signs.
The endocrine response of the heart to pressure 
or volume overload varies in relation to whether the 
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Fig 3. BNP plasma levels in 
relation to treatment time 
(pannel a) and correlation 
between BNP plasma levels 
(in %) and BNP mRNA 
expression in the LV (pannel 
b). Panel a: values are 
expressed as mean ±SEM, 
n = 6-13. * p < 0.05, ** p < 
0.001 versus sham. † p < 0.05 
versus RV2; § p < 0.05 versus 
RV4. Pannel b: each dot in 
the diagram represents mean 
±SEM for each group.
Fig 4. Correlation between 
systolic pressure and cardiac 
hypertrophy (pannel a) and 
correlation between ANP 
expression in the LV and 
cardiac hypertrophy (pannel 
b). Each dot in the diagram 
represents mean ±SEM for 
each group.
challenge is acute, subacute or chronic. The acute 
response to cardiomyocyte stretch results in enhanced 
secretion of ANP (exocytosis) stored in granules. ANP 
release following stretch is made at the expense of a 
depletable NP cytoplasmatic pool with no apparent 
effect on synthesis in the atrium. (11) In chronic 
hypertensive stage, increased ANP mRNA expression 
is more important in the ventricles than in the atria 
(18, 20, 36). ANP is secreted via a constitutive pathway. 
Thus, we find enhanced PN mRNA expression in the 
ventricles but not in the atria.
In the model studied, cardiac hypertrophy and left 
ventricular hypertrophy had a common pattern: both 
were time-dependent with a time-window between 
4 to 6 weeks in which parameters remained stable. 
BNP expression increased earlier in both ventricles, 
compared to ANP. However, as ANP expression is 
closely related to cardiac hypertrophy, when ANP 
expression values increase as a consequence of 
significant hypertrophy of both ventricles they are 
higher than those of BNP. Therefore, BNP might 
respond selectively to pressure overload, while ANP 
might be more related to cardiac hypertrophy. When we 
compare these results with those previously reported 
(23) studying RV model, DOCA-salt model (where 
volume overload predominates) and the combination 
of both models in inverse sequence, we find that 
DOCA-Salt model did not increase BNP mRNA, 
while ANP expression increased early at 2 weeks 
after treatment and showed a significant increase ay 
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RESUMEN
Participación de los péptidos natriuréticos en la 
hipertensión renovascular y su correlación con la 
evolución de la hipertrofia de miocardio
Durante la hipertensión arterial, las interacciones entre las 
sobrecargas de presión y volumen conducen a diferentes 
patrones de hipertrofia cardíaca y a un aumento de los 
péptidos natriuréticos (PN). Los perfiles de síntesis y 
secreción de ANP y BNP se han investigado en modelos de 
hipertensión arterial. Sin embargo, aún no se ha estudiado su 
evolución diferencial durante períodos agudos y crónicos de la 
hipertrofia cardíaca producida por sobrecarga de presión. Por 
este motivo estudiamos ratas Sprague-Dawley con el modelo 
1 riñón-1 clip a las 2, 4, 6 y 12 semanas, correlacionando 
la evolución de dichos perfiles con la hipertrofia cardíaca 
y la hipertensión arterial. Observamos una correlación 
positiva entre la elevación de la presión arterial y el grado 
de hipertrofia cardíaca, presentando ambos parámetros 
un incremento dependiente del tiempo a partir de las 2 
semanas. La expresión del BNP mostró un aumento precoz 
a las 2 semanas de tratamiento, mientras que el ANP se 
incrementó significativamente a las 6 semanas. No obstante, 
la expresión del ANP aumentó en forma gradual, lo que 
permitió sucorrelación con la hipertrofia y la hipertensión. 
En estadios tempranos del desarrollo de la hipertrofia 
producida por el modelo renovascular, la expresión de los 
PN respondería en forma diferencial, incrementándose en 
forma precoz el BNP. Con la evolución de la hipertrofia, la 
expresión del BNP deja de ser específica y el aumento de 
ambos PN pasa a depender y a correlacionarse con el grado 
de evolución de la hipertrofia cardíaca.
Palabras clave  > Factor natriurético auricular - 
 Cardiomegalia - Hipertensión renovascular
4 weeks. Therefore, the response of NP expression 
in early stages of antihypertensive treatment would 
depend on the therapy used: enhanced BNP expression 
in the RV model and ANP in the DOCA-Salt model. In 
chronic stages, NP expression does no longer depend 
on the type of treatment but on the degree of cardiac 
hypertrophy.
Finally, we observed that BNP plasma levels 
increased by week 4, remained stable until week 6 and 
increased agian thereafter until week 12. Plasma BNP 
profile has a similar pattern to that of BNP mRNA 
expression in the left ventricle. Increased BNP plasma 
levels at 2 weeks is indicative of enhanced synthesis 
which is significant at 4 weeks. The evolution profiles 
of synthesis and endocrine secretion is similar.
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